Trial Profile
A randomized study to compare gefitinib with bevacizumab vs gefitinib in EGFR mutation positive non-small cell lung cancer in the palliative setting.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Jun 2018 New trial record